Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.62 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652059 | 1.00 | NPC1 (0.62) | NPC1RAB9AHPGDSDGAT1CA2 | |
| SCHEMBL1750579 | 1.00 | NPC1 (0.62) | NPC1RAB9AHPGDSDGAT1CA2 | |
| SCHEMBL2796740 | 0.89 | CA1 (0.62) | RAB9ADGAT1CA2CA1ALDH1A1 | |
| SCHEMBL698880 | 0.89 | CA1 (0.62) | RAB9ADGAT1CA2CA1ALDH1A1 | |
| SCHEMBL698879 | 0.89 | CA1 (0.62) | RAB9ADGAT1CA2CA1ALDH1A1 | |
| SCHEMBL11103451 | 0.89 | CA2 (0.71) | NPC1RAB9ADGAT1CA2CA1 | |
| SCHEMBL11103438 | 0.89 | CA2 (0.71) | NPC1RAB9ADGAT1CA2CA1 | |
| SCHEMBL4067128 | 0.85 | ALDH1A1 (0.71) | NPC1RAB9AHPGDSALDH1A1LMNA | |
| SCHEMBL25554375 | 0.85 | HDAC8 (0.60) | ALDH1A1MME | |
| SCHEMBL25554182 | 0.85 | HDAC8 (0.60) | ALDH1A1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20050124535-A1 | Cyclic peptide nanotube structures for molecular scale electronic and photonic devices | WORCESTER POLYTECHNIC INSTITUTE | 2005-06-09 | — | — | US | disclosed |
| US-6902720-B2 | Cyclic peptide structures for molecular scale electronic and photonic devices | WORCESTER POLYTECHNIC INSTITUTE (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030144185-A1 | Cyclic peptide structures for molecular scale electronic and photonic devices | WORCESTER POLYTECHNIC INSTITUTE | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124535-A1 | Cyclic peptide nanotube structures for molecular scale electronic and photonic devices | NPPA, NGF, QRFPR | NPC1 3127/4885RAB9A 713/4885HPGDS 4127/4885 |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | NPC1 1243/4885RAB9A 2593/4885HPGDS 158/4885 |
| US-20030144185-A1 | Cyclic peptide structures for molecular scale electronic and photonic devices | VIP, NPPA, NGLY1 | NPC1 3048/4885RAB9A 3454/4885HPGDS 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.